European Commission Seeks To Facilitate Innovative Orphan Drug Entry; Avoid Delays For Generics
This article was originally published in SRA
The European Commission has drafted an updated version of its 2003 communication on orphan drugs which, it says, should facilitate the market entry of innovative products and avoid delays to the entry of generics.
You may also be interested in...
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.